Cargando…

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?

The role of glycoprotein (Gp) IIb/IIIa receptor antagonists remains controversial and these agents are infrequently utilized during non-ST-segment elevation acute coronary syndromes (NSTE-ACS) despite American Heart Association/American College of Cardiology guidelines. Despite recommendations, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva, Matthew A, Donovan, Jennifer L, Gandhi, Pritesh J, Volturo, Gregory A
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2006
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993977/ https://www.ncbi.nlm.nih.gov/pubmed/17319468

Ejemplares similares

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
por: Howard, J. P., et al.
Publicado: (2014)

Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019)

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
por: Cho, Jung Sun, et al.
Publicado: (2010)

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics
por: Bauer, Timm, et al.
Publicado: (2010)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis
por: Li, Jiabei, et al.
Publicado: (2015)

Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors
por: Blanchart, Katrien, et al.
Publicado: (2021)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel
por: Joo, Seung-Jae, et al.
Publicado: (2015)

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Haiyan, et al.
Publicado: (2017)

Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
por: Hahn, JongSung, et al.
Publicado: (2023)

Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials
por: Sun, Binjie, et al.
Publicado: (2017)

Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis
por: Niu, Xiao-Wei, et al.
Publicado: (2017)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
por: Wang, Zhe, et al.
Publicado: (2020)

Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins
Publicado: (1990)

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant
por: Deng, Qiao, et al.
Publicado: (2020)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Effect of Platelet Glycoprotein IIb/IIIa PLA2 Polymorphism on Severity of Pulmonary Thromboembolism
por: Boroujeni, Hamid Rouhi, et al.
Publicado: (2014)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
por: Kwan, Joanne, et al.
Publicado: (2011)

Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials
por: Rigattieri, Stefano, et al.
Publicado: (2021)

Thrombin-induced platelet membrane glycoprotein IIb and IIIa complex formation. An electron microscope study
Publicado: (1981)

Glycoprotein IIb/IIIa and P2Y(12) Induction by Oligochitosan Accelerates Platelet Aggregation
por: Periayah, Mercy Halleluyah, et al.
Publicado: (2014)

A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab™) in High-Risk Patients with Percutaneous Coronary Intervention
por: Moon, Jae-Youn, et al.
Publicado: (2008)

Effects of glycoprotein IIb/IIIa receptor blocker (tirofiban) in acute coronary syndromes angiographic, scintigraphic and molecular biology studies
por: Rizk, A, et al.
Publicado: (2001)

Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis
por: De Luca, G, et al.
Publicado: (2008)

Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis
por: Zhu, Xiaolin, et al.
Publicado: (2020)

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
por: Myrda, Krzysztof, et al.
Publicado: (2021)

Relationship of Platelet Glycoprotein IIb/IIIa and CD62P With Hypercoagulable State After Oncologic Surgery
por: Zhong, Xin, et al.
Publicado: (2020)

First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction
por: Kereiakes, Dean J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v654c9phv1iot80bg80h68f84m